Kailera Therapeutics reported a significant expansion in net loss for the second quarter of 2026, primarily driven by a 418% year-over-year increase in research and development expenses. The company ended the period with a robust cash position of approximately $1.17 billion, which management expects will fund operations and multiple clinical milestones into mid-2028.
Key Highlights
- Total cash and marketable securities reached $1,171.8 million as of June 30, 2026, compared to $653.4 million at the end of 2025.
- Research and development expenses rose to $101.1 million from $19.5 million in the prior-year period, reflecting accelerated clinical development of the ribupatide portfolio.
- The global Phase 2b high-dose ribupatide injection trial is now fully enrolled, with data anticipated in mid-2027.